PRESS DIGEST - Wall Street Journal - Nov 8
Nov 8 (Reuters) - The following were the top stories in The Wall Street Journal on Thursday. Reuters has not verified these stories and does not vouch for their accuracy.
* The subprime storm that has pummeled Wall Street got worse, with two large financial firms reporting losses related to the corner of the mortgage market. American International Group Inc's (AIG.N: Cotización) net income fell 27 percent, hurt by a $2.68 billion write-down. Morgan Stanley (MS.N: Cotización) disclosed a $3.7 billion hit from subprime exposures in the current quarter.
* Democrats enter 2008 with powerful advantages. Americans by 50 percent to 35 percent prefer that a Democrat succeed U.S. President George W. Bush, according to a WSJ/NBC poll, but Senator Hillary Clinton is still vulnerable.
* The U.S. is recalling over four million Chinese-made Aqua Dots toys after reports of children being sickened by a chemical contained in beads they swallowed.
* Cisco Systems Inc (CSCO.O: Cotización) posted a 37 percent jump in profit and a 17 percent increase in sales in its fiscal first quarter, yet the computer-networking giant disappointed investors by offering no change to its forecast.
* The Bush administration blocked a Marine Corps lawyer from testifying before Congress that severe interrogation techniques had derailed his prosecution of a suspected al Qaeda terrorist.
* Italy's Enel SPA (ENEI.MI: Cotización) is investing up to $6 billion in Russia to tap the country's vast power market, but the move carries risks.
* TiVo Inc (TIVO.O: Cotización), a provider of digital video recorders, is pushing a new service that offers advertisers detailed profiles of its users' TV-watching habits.
* Merck & Co's (MRK.N: Cotización) canceled experimental HIV vaccine may have made recipients more susceptible to HIV infection, data suggest. This has prompted researchers to warn participants in other trials that similarly made vaccines for a range of other diseases might also increase their susceptibility to HIV. Continuación...